(R)-1-(4-Difluoromethoxy-phenyl)-2-phenyl-ethylamine | 948576-10-1

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: (R)-1-(4-Difluoromethoxy-phenyl)-2-phenyl-ethylamine
• 英文别名: (1R)-1-[4-(difluoromethoxy)phenyl]-2-phenylethanamine
• CAS: 948576-10-1
• 化学式: C₁₅H₁₅F₂NO
• 分子量: 263.287
• InChiKey: XFBFFCSLXVXLOW-CQSZACIVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (R)-1-(4-Difluoromethoxy-phenyl)-2-phenyl-ethylamine 在 三氟乙酸 作用下， 以 乙醇 为溶剂， 生成 C₂₅H₂₈F₂N₂O₆S
  参考文献：
  名称：

  Arylpropanolamines: Selective β3 agonists arising from strategies to mitigate phase I metabolic transformations

  摘要：

  Utilization of N-substituted-4-hydroxy-3-methylsulfonanilidoethanolamines I as selective beta(3) agonists is complicated by their propensity to undergo metabolic oxidative N-dealkylation, generating 0.01-2% of a very potent alpha(1) adrenergic agonist 2. A summary of the SAR for this hepatic microsomal conversion precedes presentation of strategies to maintain the advantages of chemotype I while mitigating the consequences of N-dealkylation. This effort led to the identification of 4-hydroxy-3-methylsulfonanilidopropanolamines 15 for which the SAR for the unique stereochemical requirements for binding to the P adrenergic receptors culminated in the identification of the potent, selective 03 agonist 15f (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.05.030
• 作为产物：
  描述：

  (R)-2-[(R)-1-(4-Difluoromethoxy-phenyl)-2-phenyl-ethylamino]-2-phenyl-ethanol 在 lead(IV) acetate 、 盐酸 作用下， 以 甲醇 为溶剂， 生成 (R)-1-(4-Difluoromethoxy-phenyl)-2-phenyl-ethylamine
  参考文献：
  名称：

  BMS-196085: A potent and selective full agonist of the human β3 adrenergic receptor

  摘要：

  A series of 4-hydroxy-3-methylsulfonanilido-1,2-diarylethylamines were prepared and evaluated for their human beta (3) adrenergic receptor agonist activity. SAR studies led to the identification of BMS-196085 (25), a potent beta (3) full agonist (K-i = 21 nM, 95% activation) with partial agonist (45%) activity at the beta (1) receptor. Based on its desirable in vitro and in vivo properties, BMS-196085 was chosen for clinical evaluation. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00629-1